The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

The Silent Crisis

The Silent Crisis

“Fungal infections are an overlooked emerging disaster” Kainz et al., Microbial Cell, June 2020

Our Team

 

Tine Kold Olesen
PhD, MBA
Chief Executive Officer
Niels Laursen
MBA,
Chief Financial Officer
Peder M. Andersen
MD,
Chief Medical Officer
Professional
experience
Professional
experience
Pofessional
experience
  • Tine holds 148,000 shares

  • Senior roles with experience from directing global, integrated development programs from early clinical stage to life cycle management primarily in the field of urology/oncology (Ferring 19 Years). The responsibilities included design and execution of novel strategies from early (first in man) stage through marketing authorization with key focus on CMC, clinical development, and regulatory interactions.

  • Junior roles within neurology (Novo nordisk, Glaxo Welcome and Orion)

  • Vice President in the development of biosimilars and active in alliance management (Alvotech 2 years)
  • Niels Laursen holds 42,856 shares

  • Currently Owner at Dwork, offering Strategic consulting and business development

  • Formerly CFO at Oncology Venture

  • CFO at Medical Prognosis Institute

  • Healthcare Innovation Manager at Blue Ocean Robotics

  • Director HR at TopoTarget A/S
  • Peder Andersen holds 1,533,431 shares and 56,500 Investor warrants through his wholly owned company Fred Management ApS

  • Chief Executive Officer at Biosergen AS since 2017

  • As CEO at Forward Pharma from 2012-2017, he was heading all development and IP activities and was instrumental in the IPO on the NY Nasdaq (USD 235m)

  • Managing director at Forward Pharma GmbH from 2009-2016

  • Vice President of clinical development at Astion Pharma from 2010-2012
Educational
background
 
 Educational
background
Educational
background
  • PhD. Medical and Health Sciences, Ghent University

  • MSc. Pharmaceutical Sciences, Copenhagen University

  • MBA. COO. Imperial College, London
  • MBA, cand.merc from Copenhagen Business School
  • Doctor of Medicine (MD) from Copenhagen University